Skip to main content

Illumina Expects to Pocket $83.6M in Stock Placement

NEW YORK, May 19 (GenomeWeb News) - Illumina announced today that it will sell 3.5 million shares of its common stock for $25.50 apiece.

 

The company expects to receive net proceeds of about $83.6 million from the sale. Illumina last week disclosed its intent to sell the shares, but did not disclose the per-share price. The shares closed down at $25.90 yesterday.

 

Illumina has granted the underwriters of the offering the right to purchase an additional 525,000 shares of common stock.

 

Goldman Sachs and Merrill Lynch are acting as joint bookrunning and co-lead managers of the offering, while Cohen and Company and Robert W. Baird are acting as co-managers.

The Scan

US Supports Patent Waivers

NPR reports that the Biden Administration has announced its support for waiving intellectual property protections for SARS-CoV-2 vaccines.

Vaccines Versus Variants

Two studies find the Pfizer-BioNTech SARS-CoV-2 vaccine to be effective against viral variants, and Moderna reports on booster shots to combat variants.

CRISPR for What Ails You

The Wall Street Journal writes that CRISPR-based therapies could someday be used to treat common conditions like heart attacks.

Nature Papers Review Integration of Single-Cell Assay Data, Present Approach to Detect Rare Variants

In Nature this week: review of ways to integrate data from single-cell assays, and more.